MedTrace Logo

Carbapenem and Quinolone Resistance in Klebsiella Pneumoniae

NCT03767283 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-01-18

No results posted yet for this study

Summary

Klebsiella pneumoniae is an important pathogen that frequently causes nosocomial community-acquired and infections, including pneumonia, urinary tract infections, bloodstream infections, pyogenic liver abscesses, and septic shock.

An emerging co-existence of carbapenems and fluoroquinolone resistance in Klebsiella pneumoniae is causing major difficulty in treating infections caused by such pathogen

Conditions

  • Antibiotic Resistant Strain

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
2 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-05
Primary Completion
2021-06-10
Completion
2021-12-07

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03767283 on ClinicalTrials.gov